The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KRYS | +41.78% | +248.76% | +28.35% | +2,347% |
| S&P | +17.45% | +75.43% | +11.88% | +169% |
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
These two biotechs only have one marketable therapy each, but both have blockbuster potential.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $107.11M | 17.5% |
| Gross Profit | $98.95M | 17.0% |
| Gross Margin | 92.39% | -0.4% |
| Market Cap | $7.15B | 58.7% |
| Market Cap / Employee | $24.23M | 0.0% |
| Employees | 295 | 7.3% |
| Net Income | $51.40M | 13.0% |
| EBITDA | $46.03M | 7.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $496.30M | 43.9% |
| Accounts Receivable | $127.43M | 21.7% |
| Inventory | 40.5 | 52.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.57M | 25.2% |
| Short Term Debt | $1.77M | 45.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 17.14% | 7.6% |
| Return On Invested Capital | -7.63% | 3.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $75.37M | 44.8% |
| Operating Free Cash Flow | $77.51M | 46.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 43.42 | 27.96 | 26.48 | 36.02 | -31.30% |
| Price to Book | 5.49 | 4.03 | 4.91 | 6.28 | 23.48% |
| Price to Sales | 16.15 | 11.38 | 14.11 | 19.17 | 18.93% |
| Price to Tangible Book Value | 5.49 | 4.03 | 4.91 | 6.28 | 23.48% |
| Price to Free Cash Flow TTM | 41.65 | 22.05 | 31.80 | 39.48 | 0.50% |
| Enterprise Value to EBITDA | 126.38 | 83.65 | 105.74 | 144.23 | 51.48% |
| Free Cash Flow Yield | 2.4% | 4.5% | 3.1% | 2.5% | -0.50% |
| Return on Equity | 13.9% | 15.6% | 19.7% | 18.9% | 82.97% |
| Total Debt | $9.66M | $9.68M | $9.51M | $9.34M | 28.62% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
